Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2023; 15(3): 393-409
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.393
mRNA transcriptome profiling of human hepatocellular carcinoma cells HepG2 treated with Catharanthus roseus-silver nanoparticles
Nur Asna Azhar, Siti Aishah Abu Bakar, Marimuthu Citartan, Nor Hazwani Ahmad
Nur Asna Azhar, Siti Aishah Abu Bakar, Marimuthu Citartan, Nor Hazwani Ahmad, Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas 13200, Pulau Pinang, Malaysia
Nur Asna Azhar, Nor Hazwani Ahmad, Liver Malignancies Research Program, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas 13200, Pulau Pinang, Malaysia
Siti Aishah Abu Bakar, Faculty of Bioresources and Food Industry, Universiti Sultan Zainal Abidin, Besut Campus, Besut 22200, Terengganu, Malaysia
Author contributions: Ahmad NH contributed to the methodology; Ahmad NH contributed to the validation; Azhar NA contributed to the conceptualisation; Azhar NA and Abu Bakar SA contributed to the formal analysis; Azhar NA contributed to the investigation; Ahmad NH contributed to the resources; Azhar NA, Abu Bakar SA, Citartan M and Ahmad NH contributed to the data curation; Azhar NA contributed to original draft preparation; Ahmad NH and Citartan M contributed to the review and editing; Ahmad NH and Citartan M contributed to the supervision; Ahmad NH contributed to project administration; Ahmad NH contributed to funding acquisition; all authors have read and agreed to the published version of the manuscript.
Supported by Fundamental Research Grant Scheme from the Malaysian Ministry of Higher Education, No. FRGS/1/2015/SG03/USM/03/1.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nor Hazwani Ahmad, PhD, Senior Lecturer, Department of Biomedical Science, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Jalan Tun Hamdan Sheikh Tahir, Kepala Batas 13200, Pulau Pinang, Malaysia. norhazwani@usm.my
Received: October 27, 2022
Peer-review started: October 27, 2022
First decision: December 31, 2022
Revised: January 17, 2023
Accepted: March 3, 2023
Article in press: March 3, 2023
Published online: March 27, 2023
Core Tip

Core Tip: Despite the increased attention on cancer nanomedicine which is advantageous to overcome the limitations of conventional cancer treatment, the information on the selectivity and detailed mechanisms at the cellular and molecular level remain unclear. To evaluate its selectivity effects, the proliferative activity of both liver cancer cells HepG2 and normal liver cells THLE-3 in response to Catharanthus roseus-silver nanoparticles (C. roseus-AgNPs) was assessed. To determine the possible signalling pathways induced by the C. roseus-AgNPs, the mRNA transcriptome profiling of hepatocellular carcinoma cell line HepG2 was performed, highlighting the expression of genes associated with oxidative stress, apoptosis, and cell cycle arrest. The elucidation of its selectivity effects and detailed wide genome screening would enlighten the cellular and molecular signalling pathways and provide a strong basis towards the development of C. roseus-AgNPs as an anticancer drug for liver cancer.